Email this article 
Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT Trial
- Authors: Brose M.S.1, Worden F.P.2, Newbold K.L.3, Guo M.4, Hurria A.5
-
Affiliations:
- University of Pennsylvania.
- University of Michigan Health System.
- Royal Marsden Hospital
- Eisai.
- City of Hope
- Issue: Vol 8, No 2 (2018)
- Pages: 39-52
- Section: ORIGINAL REPORT
- Published: 07.07.2018
- URL: https://ogsh.abvpress.ru/jour/article/view/346
- DOI: https://doi.org/10.17650/2222-1468-2018-8-2-39-52
- ID: 346
Cite item
Full Text
Abstract
About the authors
M. S. Brose
University of Pennsylvania.
Author for correspondence.
Email: brosem@mail.med.upenn.edu
Philadelphia, PA United States
F. P. Worden
University of Michigan Health System.
Email: fake@neicon.ru
Ann Arbor, MI United States
K. L. Newbold
Royal Marsden Hospital
Email: fake@neicon.ru
London, UK United Kingdom
M. Guo
Eisai.
Email: fake@neicon.ru
Woodcliff Lake, NJ United States
A. Hurria
City of Hope
Email: fake@neicon.ru
Duarte, CA United States
References
Supplementary files
